Oncodesign Announces a 33% Revenue Increase in 2019 and the Achievement of Financial Breakeven One Year Ahead of Schedule - Seite 3

Previously, Oncodesign’s organization was predicated on the integration of resources and skills along three axes of strategic innovation—Experimentation, Discovery and Etiology—forming the core pillars of its precision medicine platform. Through this approach the Group generated three types of income streams—Service, Partnership and Licensing—giving rise to a hybrid business model.

The quality and the growth potential of each of the assets have prompted Oncodesign to introduce a new organizational structure with business units (BUs)—Service, Biotech. The aim of the new structure, which took effect from the beginning of 2020, is to make the Group’s business activities clearer for its employees, customers, partners and investors. Each of the BUs has its own objectives and resources.

In addition, like the Oncosnipe project launched three years ago, which helped to establish the Group’s capacity for innovation by harnessing AI technologies, a third Artificial Intelligence BU will be set up during 2020 that aims to support the development of the “Drug Discovery” of the future. A senior executive is currently being hired to run it.

To finalize this new organization, Oncodesign will expand into a new building in December 2020 housing both the management team and the Biotech and AI BUs. Work on the new premises began in November next to the Group’s research facility in Dijon.

“We are confident in the growth potential of each business unit, as we look to build on the various successes already achieved through the precision medicine platform, the Service business and research partnership and licensing programs”, commented Philippe Genne, Chairman, Chief Executive Officer and Founder of Oncodesign. “Our new organization should allow us to move forward smoothly over the next five years and harness the full growth potential of each business while improving the understanding and increasing the agility of the group as a whole”.

Creation of two business units at the beginning of 2020

Oncodesign Biotech:

This BU includes the therapeutic and diagnostic portfolio derived from Nanocyclix, aims to build on existing projects and partnerships and eventually to generate new ones with targets other than kinases.

Oncodesign’s Drug Discovery programs led to the establishment of a portfolio of internal and partnership projects around the proprietary Nanocyclix medicinal chemistry platform:

• the RIPK2 program for which an immuno-inflammation drug candidate was selected in late 2019
• the LRRK2 program in Parkinson’s disease in partnership with Servier and the program in partnership with BMS
• the MNK1/2 oncology program, and
• the TEP radiotracer in lung cancer for which Oncodesign is looking for a partner with which to commence a phase III trial.

Oncodesign Biotech aims to have at least three products in clinical trials, including in oncology, by 2023.